All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Less invasive ventricular reconstruction for ischaemic heart failure

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F19%3A00008544" target="_blank" >RIV/00023884:_____/19:00008544 - isvavai.cz</a>

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1669" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1669</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ejhf.1669" target="_blank" >10.1002/ejhf.1669</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Less invasive ventricular reconstruction for ischaemic heart failure

  • Original language description

    Aims Surgical ventricular reconstruction to remodel, reshape, and reduce ventricular volume is an effective therapy in selected patients with chronic heart failure (HF) of ischaemic aetiology. The BioVentrix Revivent TC System offers efficacy comparable to conventional surgical ventricular reconstruction and is less invasive utilizing micro-anchor pairs to exclude scarred myocardium on the beating heart. Here, we present 12-months follow-up data of an international multicenter study. Methods and results Patients were considered eligible for the procedure when they presented with symptomatic HF [New York Heart Association (NYHA) class >= II], left ventricular (LV) dilatation and dysfunction caused by myocardial infarction, and akinetic and/or dyskinetic transmural scarred myocardium located in the anteroseptal, anterolateral, and/or apical regions. A total of 89 patients were enrolled and 86 patients were successfully treated (97%). At 12 months, a significant improvement in LV ejection fraction (29 +/- 8% vs. 34 +/- 9%, P < 0.005) and a reduction of LV volumes was observed (LV end-systolic and end-diastolic volume index both decreased: 74 +/- 28 mL/m(2) vs. 54 +/- 23 mL/m(2), P < 0.001; and 106 +/- 33 mL/m(2) vs. 80 +/- 26 mL/m(2), respectively, P < 0.0001). Four patients (4.5%) died in hospital and survival at 12 months was 90.6%. At baseline, 59% of HF patients were in NYHA class III compared with 22% at 12-month follow-up. Improvements in quality of life measures (Minnesota Living with Heart Failure Questionnaire 39 vs. 26 points, P < 0.001) and 6-min walking test distance (363 m vs. 416 m, P = <0.001) were also significant. Conclusions Treatment with the Revivent TC System in patients with symptomatic HF results in significant and sustained reduction of LV volumes and improvement of LV function, symptoms, and quality of life.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2019

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Journal of Heart Failure

  • ISSN

    1388-9842

  • e-ISSN

  • Volume of the periodical

    21

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    NL - THE KINGDOM OF THE NETHERLANDS

  • Number of pages

    13

  • Pages from-to

    1638-1650

  • UT code for WoS article

    000500716600001

  • EID of the result in the Scopus database

    2-s2.0-85076110294